HER2/Neu Positive Terminated Phase 3 Trials for Trastuzumab (DB00072)

IndicationStatusPhase
DBCOND0037939 (HER2/Neu Positive)Terminated3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00520975Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEUTreatment